SG11201906777TA - Phenyldifluoromethyl-substituted prolinamide compound - Google Patents
Phenyldifluoromethyl-substituted prolinamide compoundInfo
- Publication number
- SG11201906777TA SG11201906777TA SG11201906777TA SG11201906777TA SG11201906777TA SG 11201906777T A SG11201906777T A SG 11201906777TA SG 11201906777T A SG11201906777T A SG 11201906777TA SG 11201906777T A SG11201906777T A SG 11201906777TA SG 11201906777T A SG11201906777T A SG 11201906777TA
- Authority
- SG
- Singapore
- Prior art keywords
- cathepsin
- compound
- phenyldifluoromethyl
- present
- inhibitory effect
- Prior art date
Links
- -1 prolinamide compound Chemical class 0.000 title abstract 3
- 108090000613 Cathepsin S Proteins 0.000 abstract 3
- 102100035654 Cathepsin S Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 210000001185 bone marrow Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 229940122805 Cathepsin S inhibitor Drugs 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017010321 | 2017-01-24 | ||
| PCT/JP2018/001927 WO2018139438A1 (ja) | 2017-01-24 | 2018-01-23 | フェニルジフルオロメチル置換プロリンアミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906777TA true SG11201906777TA (en) | 2019-08-27 |
Family
ID=62979051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906777TA SG11201906777TA (en) | 2017-01-24 | 2018-01-23 | Phenyldifluoromethyl-substituted prolinamide compound |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10322997B2 (es) |
| EP (1) | EP3575284B1 (es) |
| JP (1) | JP7001068B2 (es) |
| KR (1) | KR102553613B1 (es) |
| CN (2) | CN110248925B (es) |
| AR (1) | AR110767A1 (es) |
| AU (1) | AU2018211735B2 (es) |
| BR (1) | BR112019014788A2 (es) |
| CA (1) | CA3050224A1 (es) |
| CO (1) | CO2019009090A2 (es) |
| CY (1) | CY1124906T1 (es) |
| DK (1) | DK3575284T3 (es) |
| ES (1) | ES2892400T3 (es) |
| HR (1) | HRP20211613T1 (es) |
| HU (1) | HUE056920T2 (es) |
| IL (1) | IL268060B (es) |
| JO (1) | JOP20190181B1 (es) |
| LT (1) | LT3575284T (es) |
| MA (1) | MA47380A (es) |
| MX (1) | MX2019008756A (es) |
| MY (1) | MY195587A (es) |
| PH (1) | PH12019501645A1 (es) |
| PL (1) | PL3575284T3 (es) |
| PT (1) | PT3575284T (es) |
| RS (1) | RS62477B1 (es) |
| SG (1) | SG11201906777TA (es) |
| SI (1) | SI3575284T1 (es) |
| TW (1) | TWI764976B (es) |
| UA (1) | UA124036C2 (es) |
| WO (1) | WO2018139438A1 (es) |
| ZA (1) | ZA201904741B (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1482924T1 (sl) * | 2002-03-05 | 2008-12-31 | Merck Frosst Canada Ltd | Katepsin cistein proteazni inhibitorji |
| JP2010121918A (ja) | 2008-11-17 | 2010-06-03 | Hiroyoshi Asada | 鍋等の取っ手部分の焼き焦げ防止具。 |
| UA106748C2 (uk) * | 2009-04-20 | 2014-10-10 | Ф. Хоффманн-Ля Рош Аг | Похідні проліну як інгібітори катепсину |
| US7893099B2 (en) * | 2009-06-11 | 2011-02-22 | Hoffman-La Roche Inc. | Cyclopentane derivatives |
| JP2012059507A (ja) | 2010-09-08 | 2012-03-22 | Panasonic Corp | 基板間接続コネクタ構造 |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| SG11201402030VA (en) * | 2011-11-11 | 2014-06-27 | Hoffmann La Roche | Process for the preparation of 1-acyl-4-phenylsulfonylprolinamide derivatives and new intermediates |
| BR112014019220A8 (pt) * | 2012-02-17 | 2017-07-11 | Hoffmann La Roche | Novos derivados de pirrolidina |
| TW201412728A (zh) * | 2012-08-21 | 2014-04-01 | Hoffmann La Roche | 新穎吡啶衍生物 |
| WO2015051479A1 (en) * | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| EP3055314B1 (en) * | 2013-10-08 | 2018-09-12 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| LT3419970T (lt) | 2016-02-26 | 2020-03-10 | F. Hoffmann-La Roche Ag | Nauji pirolidino dariniai |
-
2018
- 2018-01-23 KR KR1020197021643A patent/KR102553613B1/ko active IP Right Grant
- 2018-01-23 PL PL18744079T patent/PL3575284T3/pl unknown
- 2018-01-23 JP JP2018564576A patent/JP7001068B2/ja active Active
- 2018-01-23 JO JOP/2019/0181A patent/JOP20190181B1/ar active
- 2018-01-23 AU AU2018211735A patent/AU2018211735B2/en active Active
- 2018-01-23 BR BR112019014788-8A patent/BR112019014788A2/pt active Search and Examination
- 2018-01-23 AR ARP180100143A patent/AR110767A1/es unknown
- 2018-01-23 PT PT18744079T patent/PT3575284T/pt unknown
- 2018-01-23 SI SI201830429T patent/SI3575284T1/sl unknown
- 2018-01-23 CN CN201880008062.3A patent/CN110248925B/zh active Active
- 2018-01-23 EP EP18744079.7A patent/EP3575284B1/en active Active
- 2018-01-23 UA UAA201908429A patent/UA124036C2/uk unknown
- 2018-01-23 LT LTEPPCT/JP2018/001927T patent/LT3575284T/lt unknown
- 2018-01-23 HR HRP20211613TT patent/HRP20211613T1/hr unknown
- 2018-01-23 CA CA3050224A patent/CA3050224A1/en active Pending
- 2018-01-23 MX MX2019008756A patent/MX2019008756A/es unknown
- 2018-01-23 MA MA047380A patent/MA47380A/fr unknown
- 2018-01-23 RS RS20211299A patent/RS62477B1/sr unknown
- 2018-01-23 SG SG11201906777TA patent/SG11201906777TA/en unknown
- 2018-01-23 CN CN202010529596.XA patent/CN111574422B/zh active Active
- 2018-01-23 TW TW107102307A patent/TWI764976B/zh active
- 2018-01-23 MY MYPI2019004186A patent/MY195587A/en unknown
- 2018-01-23 DK DK18744079.7T patent/DK3575284T3/da active
- 2018-01-23 WO PCT/JP2018/001927 patent/WO2018139438A1/ja active Application Filing
- 2018-01-23 ES ES18744079T patent/ES2892400T3/es active Active
- 2018-01-23 HU HUE18744079A patent/HUE056920T2/hu unknown
- 2018-11-05 US US16/180,862 patent/US10322997B2/en active Active
-
2019
- 2019-04-25 US US16/394,571 patent/US10532979B2/en active Active
- 2019-07-15 PH PH12019501645A patent/PH12019501645A1/en unknown
- 2019-07-15 IL IL268060A patent/IL268060B/en unknown
- 2019-07-18 ZA ZA2019/04741A patent/ZA201904741B/en unknown
- 2019-08-22 CO CONC2019/0009090A patent/CO2019009090A2/es unknown
-
2021
- 2021-10-26 CY CY20211100928T patent/CY1124906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
| WO2005032465A3 (en) | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | |
| WO2003073986A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| EP1470137A4 (en) | EDG RECEPTOR AGONISTS | |
| ATE496024T1 (de) | 1-(amino)indane als edg-rezeptoragonisten | |
| WO2004103279A3 (en) | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | |
| WO2003074008A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
| TW201625535A (en) | Inhibitors of histone demethylases | |
| PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
| WO2004031129A3 (en) | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | |
| PH12021550620A1 (en) | Ophthalmic composition for treatment of dry eye disease | |
| GB0623258D0 (en) | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | |
| EP4269549A3 (en) | Skin cleansing compositions | |
| FR3089117B1 (fr) | Compositions cosmétiques déodorantes anhydres comprenant du carbonate de calcium | |
| SG11201906777TA (en) | Phenyldifluoromethyl-substituted prolinamide compound | |
| WO2019018447A3 (en) | PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATION OF ORGAN FUNCTION | |
| WO2015136237A3 (en) | Improvements in or relating to medical and veterinarian rotary tools | |
| PH12019502580B1 (en) | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio | |
| PH12019502277A1 (en) | Crystalline forms of (s)-afoxolaner | |
| MX2020008300A (es) | Uso de [6]-paradol para estabilizacion de composiciones cosmeticas. | |
| EA201491876A1 (ru) | Азотсодержащее бициклическое ароматическое гетероциклическое соединение | |
| EP4028027A4 (en) | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH AAXIA | |
| PH12019502696A1 (en) | Resorbable biodegradable medical and cosmetic composition comprising poly(1,3-trimethylene carbonate) |